Division of Pharmacology, Cluster Systems Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
Intensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands; Department of Pediatrics, Division of Neonatology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Eur J Pharm Sci. 2017 Nov 15;109S:S32-S38. doi: 10.1016/j.ejps.2017.05.027. Epub 2017 May 12.
Pain is a complex biopsychosocial phenomenon of which the intensity, location and duration depends on various underlying components. Treatment of pain is associated with considerable inter-individual variability, and as such, requires a personalized approach. However, a priori prediction of optimal analgesic treatment for individual patients is still challenging. Another challenge is the assessment and treatment of pain in patients unable to self-report pain. In this mini-review, we first provide a brief overview of the various components underlying pain, and their associated biomarkers. These include clinical, psychosocial, neurophysiological, and biochemical components. We then discuss the use of empirical and mechanism-based pharmacokinetic-pharmacodynamic modelling to support personalized treatment of pain. Finally, we propose how these concepts can be extended to a quantitative systems pharmacology (QSP) approach that integrates the components of clinical pain and treatment response. This integrative approach can support predictions of optimal pharmacotherapy of pain, compared with approaches that focus on single components of pain. Moreover, combination of QSP modelling with state-of-the-art metabolomics approaches may offer unique possibilities to identify novel pain biomarkers. Such biomarkers could support both the personalized treatment of pain and translational drug development of novel analgesic agents. In conclusion, a QSP approach will likely improve our ability to predict pain and treatment response, paving the way for personalized treatment of pain.
疼痛是一种复杂的生物心理社会现象,其强度、位置和持续时间取决于各种潜在的组成部分。疼痛的治疗与相当大的个体间变异性有关,因此需要个性化的方法。然而,预先预测个体患者的最佳镇痛治疗仍然具有挑战性。另一个挑战是评估和治疗无法自我报告疼痛的患者的疼痛。在这篇迷你综述中,我们首先简要概述了疼痛的各种潜在组成部分及其相关的生物标志物。这些包括临床、心理社会、神经生理和生化成分。然后,我们讨论了使用经验和基于机制的药代动力学-药效学模型来支持疼痛的个性化治疗。最后,我们提出了如何将这些概念扩展到一种定量系统药理学(QSP)方法,该方法将临床疼痛和治疗反应的各个组成部分整合在一起。与专注于疼痛的单个组成部分的方法相比,这种综合方法可以支持对疼痛的最佳药物治疗的预测。此外,将 QSP 建模与最先进的代谢组学方法相结合,可能为识别新的疼痛生物标志物提供独特的可能性。这些生物标志物可以支持疼痛的个性化治疗和新型镇痛药物的转化药物开发。总之,QSP 方法可能会提高我们预测疼痛和治疗反应的能力,为疼痛的个性化治疗铺平道路。